Want to see IN:HCG full AI Analyst Report?
HCG Stock Chart & Stats
₹666.25
₹10.40(1.56%)
At close: 4:00 PM EDT
₹666.25
₹10.40(1.56%)
Day’s Range― - ―
52-Week Range₹513.40 - ₹799.36
Previous CloseN/A
Volume148.81K
Average Volume (3M)18.12K
Market Cap
₹106.59B
Enterprise Value₹107.18K
Total Cash (Recent Filing)₹5.41B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)456.6
Beta0.49
Next Earnings
Nov 05, 2026EPS Estimate
1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.56
Shares Outstanding149,302,200
10 Day Avg. Volume16,611
30 Day Avg. Volume18,118
Financial Highlights & Ratios
PEG Ratio-7.78
Price to Book (P/B)5.59
Price to Sales (P/S)2.93
P/FCF Ratio135.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.87
Revenue Forecast (FY)₹29.06B
Bulls Say, Bears Say
Bulls Say
Scaled Revenue BaseRevenue growth to a much larger scale demonstrates durable demand for oncology services and successful capacity expansion. A larger scale supports clinical specialization, referral networks and better fixed-cost absorption, underpinning long-term operational resilience and potential margin recovery.
Strong Cash GenerationConsistent operating cash flow growth and positive free cash flow provide internal funding for capex, debt service and selective expansion. Robust cash generation improves financial flexibility, reduces reliance on external financing and supports sustained operations through cyclical healthcare demand.
Integrated Oncology NetworkA focused, integrated oncology platform creates durable competitive advantages: clinical specialization, patient retention and referral ecosystems. Comprehensive care across the continuum increases lifetime patient value and strengthens barriers to entry in specialized cancer services.
Bears Say
Very Thin ProfitabilityExtremely low net margins leave little buffer against cost inflation, reimbursement shifts or operational setbacks. Thin profitability constrains reinvestment, limits ability to build reserves, and makes earnings highly sensitive to interest costs and small revenue fluctuations.
High And Rising LeverageElevated debt and a materially higher leverage ratio increase interest burden and refinancing risk for a capital-intensive hospital operator. High leverage reduces strategic flexibility, raises required cash generation for coverage, and amplifies earnings volatility in adverse scenarios.
Decelerating Revenue GrowthA marked slowdown in top-line growth reduces economies of scale and delays margin improvement. Slower revenue expansion limits upside on operating leverage, prolongs payback on prior investments, and raises the bar for restoring healthier profitability levels.
HealthCare Global Enterprises Ltd. News
HCG FAQ
What was HealthCare Global Enterprises Ltd.’s price range in the past 12 months?
HealthCare Global Enterprises Ltd. lowest stock price was ₹513.40 and its highest was ₹799.36 in the past 12 months.
What is HealthCare Global Enterprises Ltd.’s market cap?
HealthCare Global Enterprises Ltd.’s market cap is ₹106.59B.
When is HealthCare Global Enterprises Ltd.’s upcoming earnings report date?
HealthCare Global Enterprises Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were HealthCare Global Enterprises Ltd.’s earnings last quarter?
HealthCare Global Enterprises Ltd. released its earnings results on Aug 06, 2026. The company reported ₹0.95 earnings per share for the quarter, missing the consensus estimate of ₹2.79 by -₹1.84.
Is HealthCare Global Enterprises Ltd. overvalued?
According to Wall Street analysts HealthCare Global Enterprises Ltd.’s price is currently Overvalued.
Does HealthCare Global Enterprises Ltd. pay dividends?
HealthCare Global Enterprises Ltd. does not currently pay dividends.
What is HealthCare Global Enterprises Ltd.’s EPS estimate?
HealthCare Global Enterprises Ltd.’s EPS estimate is 1.97.
How many shares outstanding does HealthCare Global Enterprises Ltd. have?
HealthCare Global Enterprises Ltd. has 149,302,200 shares outstanding.
What happened to HealthCare Global Enterprises Ltd.’s price movement after its last earnings report?
HealthCare Global Enterprises Ltd. reported an EPS of ₹0.95 in its last earnings report, missing expectations of ₹2.79. Following the earnings report the stock price went up 0.172%.
Which hedge fund is a major shareholder of HealthCare Global Enterprises Ltd.?
Currently, no hedge funds are holding shares in IN:HCG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Limited, founded in 1989 and headquartered in Bengaluru, India, delivers comprehensive healthcare services with a primary focus on oncology. The company offers a full spectrum of cancer care, from diagnosis to various treatment modalities such as radiation therapy, medical oncology, and surgical procedures. Beyond its core cancer services, HCG also operates in the field of fertility and reproductive medicine under its Milann brand. This includes services like assisted reproduction, gynecological endoscopy, and fertility preservation. The enterprise further manages four multi-specialty hospitals: three branded HCG facilities located in Ahmedabad, Bhavnagar, and Rajkot in Gujarat, and one in Hubli, Karnataka, operated under a management contract. These hospitals cater to diverse medical specialities including cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, pulmonary care, and critical care. Additionally, HealthCare Global provides medical diagnostic services, offering scientific testing and consultancy for the pharmaceutical and broader medical industries. As of March 31, 2021, its extensive network comprised 23 cancer centers throughout India, featuring a center of excellence in Bengaluru, alongside two independent diagnostic centers and one day-care chemotherapy unit. The company also maintains an international presence with a cancer center established in Africa.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―